Sprint Bioscience Q3 2022: Seal the deal - Redeye

Redeye comments on Sprint Bioscience’s Q3 2022 report, and we judge that the company is closing in on a licensing deal for its VADA project in late 2022e or H1 2023e. We preliminarily adjust our valuation for the company’s recently announced rights issue and increased cost control measures.

Länk till analysen i sin helhet: https://www.redeye.se/research/859726/sprint-bioscience-q3-2022-seal-the-deal?utm_source=finwire&utm_medium=RSS